Autoimmune hemolytic anemia (AIHA) is an autoimmune disorder in which the body's own antibodies attack and destroy red blood cells. Rituximab, a monoclonal antibody, is an effective treatment for AIHA. The amount of rituximab used to treat AIHA varies depending on the severity of the condition, the patient's response to other treatments, and other factors.
Dosing Recommendations
The recommended dose of rituximab for AIHA is 375 mg/m2 given in two doses, separated by two weeks. However, the exact dose may vary depending on the patient's response to treatment.
Side Effects
Rituximab has a number of side effects, including fever, chills, nausea, and fatigue. It can also cause serious, even life-threatening side effects, such as infusion reactions, infection, and organ damage. Patients should discuss all potential side effects with their healthcare provider before beginning treatment.
Monitoring and Follow-up Care
Patients receiving rituximab for AIHA should be monitored closely for signs and symptoms of infection, infusion reactions, and organ damage. Follow-up blood tests should also be done regularly to monitor the patient's response to treatment.